With Alzheimer’s market opening up, Lilly forms neuroscience unitEli Lilly is one of the front runners in the bid to follow Biogen and Eisai onto the Share XWith Alzheimer’s market opening up, Lilly forms neuroscience unithttps://pharmaphorum.com/news/lilly-forms-neuroscience-unit/
Lilly sets out its stall on donanemab as filing approachesThe FDA’s approval of Biogen’s Aduhelm for Alzheimer’s disease has emboldened Eli Lilly to move forward plans to Share XLilly sets out its stall on donanemab as filing approacheshttps://pharmaphorum.com/news/lilly-sets-out-its-stall-on-donanemab-as-filing-approaches/
BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyJust a few days after Biogen abandoned its tau-targeting Alzheimer’s disease candidate gosuranemab, Bristol-Myers Squibb has opted into Share XBMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyhttps://pharmaphorum.com/news/bms-re-joins-alzheimers-push-paying-80m-for-prothenas-tau-antibody/
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a Share XCould Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/
